BlackRock Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.73M	Buy	106,963 +7,045	+7%	+$128K	﹤0.01%	1870
2016 Q3	$1.81M	Sell	99,918 -3,973	-4%	-$77.6K	﹤0.01%	1689
2016 Q2	$1.71M	Buy	103,891 +2,972	+3%	+$48.1K	﹤0.01%	1646
2016 Q1	$1.67M	Buy	100,919 +17,505	+21%	+$306K	﹤0.01%	1643
2015 Q4	$1.81M	Buy	83,414 +1,142	+1%	+$22.2K	﹤0.01%	1545
2015 Q3	$1.63M	Sell	82,272 -162,848	-66%	-$5.15M	﹤0.01%	1612
2015 Q2	$8.52M	Buy	+245,120	New	+$7.48M	﹤0.01%	1007
2014 Q3	–	Sell	-37,522	Closed	-$593K	–	2906
2014 Q2	$593K	Buy	+37,522	New	+$536K	﹤0.01%	2130

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Group's HZNP Position: Q4 2016 in Review

BlackRock Group increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 7.1% in Q4 2016, buying an estimated $128K and bringing the position to 106,963 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

BlackRock Group first reported a position in HZNP in Q2 2014 and has held it in 8 quarters since. The position peaked at $8.52M in Q2 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

BlackRock Group held 106,963 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $1.73M as of Q4 2016.
BlackRock Group bought 7,045 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $128K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1870 holding.
BlackRock Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and has held it in 8 quarters since.
BlackRock Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.52M in Q2 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.